In vivo selection yields AAV-B1 capsid for CNS and muscle gene therapy.
Choudhury SR, Fitzpatrick Z, Harris AF, Maitland SA, Ferreira JS, Zhang Y, Ma S, Sharma RB, Gray-Edwards HL, Johnson JA, Johnson AK, Alonso LC, Punzo C, Wagner KR, Maguire CA, Kotin RM, Martin DR, Sena-Esteves M
Mol Ther. 2016 Apr 27. doi: 10.1038/mt.2016.84. PubMed Article
Choudhury SR, Fitzpatrick Z, Harris AF, Maitland SA, Ferreira JS, Zhang Y, Ma S, Sharma RB, Gray-Edwards HL, Johnson JA, Johnson AK, Alonso LC, Punzo C, Wagner KR, Maguire CA, Kotin RM, Martin DR, Sena-Esteves M
Mol Ther. 2016 Apr 27. doi: 10.1038/mt.2016.84. PubMed Article
Plasmids from Article
| ID | Plasmid | Purpose |
|---|---|---|
| 78503 | pAR-B1(1986.1) | Trans plasmid for production of recombinant AAV-B1 vectors. Plasmid encodes AAV2 Rep and AAV-B1 capsid |
| 78504 | pGG-B1 | Trans plasmid for production of recombinant AAV-B1 vectors. Plasmid backbone may yield higher titers than pAR-B1 and encodes AAV2 Rep and AAV-B1 capsid |